GH Research Financial Statements
NASDAQ: GHRSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
21.11+0.66 (+3.23%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
GH Research revenue and earnings
GH Research reported a net loss of $48.3 million, compared with a loss of $39.0 million a year earlier. Diluted earnings per share came in at -$0.79.
Summary generated from market data by MetaCap's automated system. Methodology
GH Research income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 |
|---|---|---|---|---|---|---|---|
| Operating Expenses | 60.72M | 50.31M | 41.22M | 30.55M | 15.10M | 446.00K | 310.00K |
| Research & Development | 38.77M | 35.02M | 29.82M | 20.48M | 8.55M | 338.00K | 296.00K |
| Selling, General & Admin | 21.95M | 15.30M | 11.40M | 10.07M | 6.55M | 108.00K | 14.00K |
| Operating Income | -60.72M | -50.31M | -41.22M | -30.55M | -15.10M | -446.00K | -310.00K |
| Interest Expense | 463.00K | 717.00K | 723.00K | 123.00K | 9.00K | 0 | 0 |
| Pretax Income | -48.26M | -38.96M | -35.59M | -22.46M | -9.20M | -446.00K | -310.00K |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -48.26M | -38.96M | -35.59M | -22.46M | -9.20M | -446.00K | -310.00K |
| Net Income growth (YoY) | — | — | — | — | — | — | — |
| EPS (Basic) | -0.79 | -0.75 | -0.68 | -0.43 | -0.21 | -0.016 | -0.011 |
| EPS (Diluted) | -0.79 | -0.75 | -0.68 | -0.43 | -0.21 | -0.016 | -0.011 |
| Shares Outstanding (Basic) | 61.04M | 52.03M | 52.02M | 52.02M | 43.68M | 28.36M | 28.00M |
| EBITDA | -60.38M | -50.00M | -40.91M | -30.51M | -15.08M | -446.00K | -310.00K |
This table shows 7 annual periods of GH Research's income statement, from FY 2025 back to FY 2019, across 12 line items including operating expenses, research & development, selling, general & admin. Values in USD; B = billions, M = millions. Fiscal periods follow GHRS's reporting calendar. What is a income statement?